The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix

Gynecologic Oncology

Volumn 104, Issue 3, 2007, Pages 732-738

  Song, Seung Hun ^a,b   Lee, Jae Kwan ^a,b   Seok, Oye Sun ^b   Saw, Ho Suk ^a,b  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

Human papillomavirus (HPV); Interferon (IFN ); Interleukin 10 (IL 10); Interleukin 6 (IL 6); Tumor necrosis factor (TNF )

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VIRUS DNA;

ADULT; AGED; ARTICLE; CYTOKINE RELEASE; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; UTERINE CERVIX; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD;

EID: 33846908537     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.10.054     Document Type: Article

References (49)

1. Ambros R.A., and Kurman R.J. Current concepts in the relationship of human papillomavirus infection to the pathogenesis and classification of precancerous squamous lesions of the uterine cervix. Sem. Diagn. Pathol. 7 (1990) 158-172
2. Kjaer S.K., van den Brule A.J., Paull G., Svare E.I., Sherman M.E., Thomsen B.L., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 325 (2002) 572-578
3. zur Hausen H. Papillomavirususes causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92 (2000) 690-698
4. Josefsson A.M., Magnusson P.K., Ylitalo N., Sorensen P., Qwarforth-Tubbin P., Andersen P.K., et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2189-2193
5. Sellors J.W., Mahony J.B., Kaczorowski J., Lytwyn A., Bangura H., Chong S., et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ 163 (2000) 503-508
6. Nobbenhuis M.A., Walboomers J.M., Helmerhorst T.J., Rozendaal L., Remmink A.J., Risse E.K., et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354 (1999) 20-25
7. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsaque X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348 (2003) 518-527
8. Wettstein F.O. State of viral DNA and gene expression in benign vs. malignant tumors. In: Pfister H. (Ed). Papillomaviruses and human cancer (1990), CRC Press, Florida 145
9. Seedorf K., Oltersdorf T., Krammer G., and Rowekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J. 6 (1987) 139-144
10. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189 (1999) 12-19
11. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. 87 (1995) 796-802
12. von Knebel Doebertiz M., Oltersdorf T., Schwarz E., and Gissmann L. Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res. 48 (1998) 3780-3786
13. van Duin M., Snijders P.J., Schrijnemakers H.F., Voorhorst F.J., Rozendaal L., Nobbenhuis M.A., et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int. J. Cancer 98 (2002) 590-595
14. Dalstein V., Riethemuller D., Pretet J.L., Le Bail Carval K., Sautiere J.L., Carbillet J.P., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int. J. Cancer 106 (2003) 396-403
15. Moberg M., Gustavsson I., and Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int. J. Cancer 112 (2004) 854-859
16. Ho G.Y., Burk R.D., Klein S., Kadish A.S., Chang C.J., Palan P., et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J. Natl. Cancer Inst. 87 (1995) 1365-1371
17. Kyo S., Inoue M., Hayasaka N., Inoue T., Yutsudo M., Tanizawa O., et al. Regulation of early gene expression of human papillomavirus type 16 by inflammatory cytokines. Virology 200 (1994) 130-139
18. Spellberg B., and Edwards Jr. J.E. Type 1/Type 2 immunity in infectious diseases. Clin. Infect. Dis. 32 (2001) 76-102
19. Clerici M., and Shearer G.M. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol. Today 15 (1994) 575-581
20. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev., Cancer 2 (2002) 342-350
21. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev., Immunol. 3 (2003) 745-756
22. Wu T.C., and Kurman R.J. Analysis of cytokine profiles in patients with human papillomavirus-associated neoplasms. J. Natl. Cancer Inst. 89 (1997) 185-187
23. Scott M., Nakagawa M., and Moscicki A.B. Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol. 8 (2001) 209-220
24. Wei L.H., Kuo M.L., Chen C.A., Chen W.F., Cheng S.P., Hsieh F.J., et al. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol. Oncol. 82 (2001) 49-56
25. Arany I., Grattendick K.G., and Tyring S.K. Interleukin-10 induces transcription of the early promoter of human papillomavirus type 16 (HPV 16) through the 5-segment of the upstream regulatory region (URR). Antivir. Res. 55 (2002) 331-339
26. Wang-Johanning F., Lu D.W., Wang Y., Johnson M.R., and Johanning G.L. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 94 (2002) 2199-2210
27. Fernandes A.P., Goncalves M.A., Duarte G., Cunha F.Q., Simoes R.T., and Donadi E.A. HPV 16, HPV 18, and HIV infection may influence cervical cytokine intralesional levels. Virology 334 (2005) 294-298
28. Amed M.I., Salahy E.E., Fayed S.T., El-Hefnawy N.G., and Khalifa A. Human papillomavirus infection among Egyptian females with cervical carcinoma: relationship to spontaneous apoptosis and TNF-alpha. Clin. Biochem. 34 (2001) 491-498
29. Pao C.C., Lin C.Y., Yao D.S., and Tsen C.J. Differential expression of cytokine genes in cervical cancer tissues. Biochem. Biophys. Res. Commun. 214 (1995) 1146-1151
30. Merrick D.T., Winberg G., and McDougall J.K. Re-expression of interleukin 1 in human papillomavirus 18 immortalized keratinocytes inhibits their tumorigenicity in nude mice. Cell Growth Differ. 7 (1996) 1661-1669
31. Woodworth C.D., and Simpson S. Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomarvirus-immortalized, and carcinoma cell lines. Am. J. Pathol. 142 (1993) 1544-1555
32. Man S. Human cellular immune responses against human papillomaviruses in cervical neoplasia. Expert Rev. Mol. Med. (1998) 1-19
33. van der Burg S.H., Ressing M.E., Kwappenberg K.M., de Jong A., Straathof K., de Jong J., et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV 16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int. J. Cancer 91 (2001) 612-618
34. Welters M.J., de Jong A., van den Eeden S.J., van der Hulst J.M., Kwappenberg K.M., Hassane S., et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 63 (2003) 636-641
35. Bontkes H.J., de Gruijl T.D., van den Muysenberg A.J., Verheijen R.H., Stukart M.J., Meijer C.J., et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int. J. Cancer 88 (2000) 92-98
36. Kadish A.S., Timmins P., Wang Y., Ho G.Y., Burk R.D., Ketz J., et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol., Biomarkers Prev. 11 (2002) 483-488
37. Cheng W.F., Lee C.N., Su Y.N., Chang M.C., Hsiao W.C., Chen C.A., et al. Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology 115 (2005) 136-149
38. Ylitalo N., Sorensen P., Josefsson A.M., Magnusson P.K., Andersen P.K., Ponten J., et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 355 (2000) 2194-2198
39. Flores R., Papenfuss M., Klimecki W.T., and Giuliano A.R. Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia. Int. J. Cancer 118 (2006) 1187-1193
40. Sun C.A., Lai H.C., Chang C.C., Neih S., Yu C.P., and Chu T.Y. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol. Oncol. 83 (2001) 95-99
41. Tjiong M.Y., van der Vange N., ten Kate F.J., Tjong-A-Hung S.P., ter Schegget J., Burger M.P., et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. Gynecol. Oncol. 73 (1999) 285-291
42. Bais A.G., Beckmann I., Lindemans J., Ewing P.C., Meijer C.J., Snijders P.J., et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J. Clin. Pathol. 58 (2005) 1096-1100
43. Azar K.K., Tani M., Yasuda H., Sakai A., Inoue M., and Sasagawa T. Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum. Pathol. 35 (2004) 1376-1384
44. Niwa Y., Akamatsu H., Niwa H., Sumi H., Ozaki Y., and Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin. Cancer Res. 7 (2001) 285-289
45. Jacobs N., Giannini S.L., Doyen J., Baptista A., Moutschen M., Boniver J., et al. Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clin. Exp. Immunol. 111 (1998) 219-224
46. Hildesheim A., McShane L.M., Schiffman M., Bratti M.C., Rodriguez A.C., Herrero R., et al. Cytokine and immunoglobulin concentrations in cervical secretions: reproducibility of the Weck-cel collection instrument and correlates of immune measures. J. Immunol. Methods 225 (1999) 131-143
47. Castle P.E., Hildesheim A., Bowman F.P., Strickler H.D., Walker J.L., Pustilnik T., et al. Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J. Clin. Immunol. 22 (2002) 23-27
48. Crowley-Nowick P.A., Ellenberg J.H., Vermund S.H., Douglas S.D., Holland C.A., and Moscicki A.B. Cytokine profile in genital tract secretions from female adolescents: impact of human immunodeficiency virus, human papillomavirus, and other sexually transmitted pathogens. J. Infect. Dis. 181 (2000) 939-945
49. Gravitt P.E., Hildesheim A., Herrero R., Schiffman M., Sherman M.E., Bratti M.C., et al. Correlates of IL-10 and IL-12 concentrations in cervical secretions. J. Clin. Immunol. 23 (2003) 175-183